Pirfenidone is a medicine used to manage lung scarring. Balancing restorative signals in the breathing system, this treatment slows the progression of damage and improves overall capacity.
When scar tissue builds up in the lungs, breathing can become harder and everyday activities may feel exhausting. Pirfenidone belongs to a group of drugs called antifibrotics, which are designed to slow the formation of this scar tissue. Its main therapeutic purpose is to help preserve lung function in people with progressive lung scarring. The active compound is found in medicines such as Esbriet, which are approved for use in Singapore.
The drug works over many months, not as a quick fix, and it is usually taken regularly as part of a broader care plan. Because it targets a specific process in the lungs, it is not used for infections or asthma. Patients often hear the name Pirfenidone when they discuss treatment options for certain chronic lung conditions.
Several authorized products in Singapore incorporate Pirfenidone, the most recognizable being Esbriet. These medicines are available in oral tablet form that patients swallow with water. Generic versions may exist, but they contain the same active ingredient and follow the same regulatory standards as the brand name product. Whether a tablet is labeled as Esbriet or as a generic, the ingredient remains Pirfenidone, and the medication is meant to be taken according to the product’s instructions.
People diagnosed with idiopathic pulmonary fibrosis (IPF) often receive treatments that include this antifibrotic agent. IPF is a type of interstitial lung disease where the lung tissue becomes thickened and loses its elasticity. Pirfenidone is also sometimes considered for other progressive fibrotic lung conditions when a doctor deems it appropriate. It is generally offered to adults who show a steady decline in lung capacity despite other supportive measures.
In simple terms, Pirfenidone interferes with the body's tendency to lay down excess collagen, the protein that creates scar tissue. By reducing this over-production, the medication helps keep the lungs more flexible and may slow the worsening of symptoms such as shortness of breath. It does not reverse existing scarring, but it can help manage the disease’s progression.
Mild nausea, loss of appetite, and a slight increase in stomach discomfort are frequently reported. Some people notice a mild rash or a temporary change in taste that usually resolves on its own.
Rarely, individuals may develop severe skin reactions, liver enzyme abnormalities, or persistent coughing that worsens. If these symptoms appear, prompt medical attention is advised.
Pregnant or breastfeeding individuals should avoid using this medication. People with known hypersensitivity to Pirfenidone or similar compounds should not take it. Severe liver disease also warrants caution.
Alcohol can increase the likelihood of liver-related side effects, and certain medicines that affect liver metabolism may alter Pirfenidone levels. Readers should refer to their medication’s labeling or package information for precise interaction details.
During treatment, tablets should be stored at room temperature away from excess heat and moisture. Treatment duration often extends for many months, and the medication’s effect is evaluated over time. Different products such as Esbriet may have slight variations in tablet size or coating, but the core ingredient remains the same. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This article provides an educational overview of Pirfenidone and is not medical advice. Medicines containing this ingredient, such as Esbriet, may differ in formulation, strength, and directions. The information herein does not replace professional clinical judgment. Readers should review the labeling of their specific medication and seek guidance from a qualified healthcare professional for any health-related decisions.
Additional details can be found at the following sites:
